2012
DOI: 10.1371/journal.pone.0041016
|View full text |Cite
|
Sign up to set email alerts
|

Affibody-DyLight Conjugates for In Vivo Assessment of HER2 Expression by Near-Infrared Optical Imaging

Abstract: PurposeAmplification of the HER2/neu gene and/or overexpression of the corresponding protein have been identified in approximately 20% of invasive breast carcinomas. Assessment of HER2 expression in vivo would advance development of new HER2-targeted therapeutic agents and, potentially, facilitate choice of the proper treatment strategy offered to the individual patient. We present novel HER2-specific probes for in vivo evaluation of the receptor status by near-infrared (NIR) optical imaging.Experimental Desig… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
28
0

Year Published

2013
2013
2017
2017

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 20 publications
(29 citation statements)
references
References 31 publications
1
28
0
Order By: Relevance
“…Comparisons of the pharmacokinetics and targeting of intact and antibody fragments (enzymatically-derived and recombinant) have been conducted; recent examples include targeted imaging of prostate-specific membrane antigen (PSMA) using 111 In-radiolabeled F(ab′) 2 and Fab (Fragment antigen binding) fragments, and 89 Zr-labeled minibodies and diabodies with small animal SPECT or PET (Lütje et al, 2014c; Viola-Villegas et al, 2014). Continued interest in smaller antibody fragments and protein scaffolds is evidenced by several imaging studies with nanobodies (Bannas et al, 2014; De Vos et al, 2014; Massa et al, 2014) and affibodies (Kim et al, 2014; Strand et al, 2014; Zielinski et al, 2012). Nanobodies (~15kDa) are single-domain variable heavy chain (V H H) fragments, which are derived from heavy chain-only antibodies found in camelids (Schoonooghe et al, 2012), while affibodies (~7kDa) are based on Staphylococcus aureus protein A (Zielinski et al, 2012).…”
Section: Development Of Antibodies and Fragments For In Vivo Imagingmentioning
confidence: 99%
See 2 more Smart Citations
“…Comparisons of the pharmacokinetics and targeting of intact and antibody fragments (enzymatically-derived and recombinant) have been conducted; recent examples include targeted imaging of prostate-specific membrane antigen (PSMA) using 111 In-radiolabeled F(ab′) 2 and Fab (Fragment antigen binding) fragments, and 89 Zr-labeled minibodies and diabodies with small animal SPECT or PET (Lütje et al, 2014c; Viola-Villegas et al, 2014). Continued interest in smaller antibody fragments and protein scaffolds is evidenced by several imaging studies with nanobodies (Bannas et al, 2014; De Vos et al, 2014; Massa et al, 2014) and affibodies (Kim et al, 2014; Strand et al, 2014; Zielinski et al, 2012). Nanobodies (~15kDa) are single-domain variable heavy chain (V H H) fragments, which are derived from heavy chain-only antibodies found in camelids (Schoonooghe et al, 2012), while affibodies (~7kDa) are based on Staphylococcus aureus protein A (Zielinski et al, 2012).…”
Section: Development Of Antibodies and Fragments For In Vivo Imagingmentioning
confidence: 99%
“…Continued interest in smaller antibody fragments and protein scaffolds is evidenced by several imaging studies with nanobodies (Bannas et al, 2014; De Vos et al, 2014; Massa et al, 2014) and affibodies (Kim et al, 2014; Strand et al, 2014; Zielinski et al, 2012). Nanobodies (~15kDa) are single-domain variable heavy chain (V H H) fragments, which are derived from heavy chain-only antibodies found in camelids (Schoonooghe et al, 2012), while affibodies (~7kDa) are based on Staphylococcus aureus protein A (Zielinski et al, 2012). The small sizes of these fragments enable them to bind to epitopes that antibody Fv-based fragments cannot access (Schoonooghe et al, 2012) and makes them suitable for applications in which extremely rapid clearance is desired.…”
Section: Development Of Antibodies and Fragments For In Vivo Imagingmentioning
confidence: 99%
See 1 more Smart Citation
“…As discussed in a recent review on quantitative PET imaging in oncology (Tomasi et al , 2012), this assumption has only been validated in brain-tissue imaging, and it is known that the factors that influence K 1 and k 2 can be highly abnormal in tumors (Jain, 2001). There are a few studies that have employed reference tissue models for cancer imaging (Ardeshirpour et al , 2014; Chernomordik et al , 2010; Hassan et al , 2012; Zielinski et al , 2012; Guo et al , 2012; Zhang et al , 2006; Zhu et al , 2012); however, a recent study from our group demonstrates that tumors can have variable and odd K 1 / k 2 ratios that can make it difficult to identify a suitable reference tissue from any healthy tissue (Tichauer et al , 2012a). …”
Section: Quantitative Kinetic Modelingmentioning
confidence: 99%
“…Affibody molecules are small, soluble, robust affinity ligands that were developed from the B domain of staphylococcal protein A (26). HER2 affibodies possess high affinity and high selectivity (25) and have been used for tumor labeling and targeting (27). The HER2 affibody ZHER2:2891 binds to HER2 with high affinity and is internalized by HER2-expressing cells (25,28).…”
Section: Introductionmentioning
confidence: 99%